Journal
JOURNAL OF BIOLOGICAL CHEMISTRY
Volume 286, Issue 50, Pages 43429-43436Publisher
AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
DOI: 10.1074/jbc.M111.299339
Keywords
-
Categories
Funding
- National Institutes of Health [R01 AI42269, R01 AI49954, R01 AI85567]
- Deutsche Forschungsgemeinschaft [RA1927-1/1]
Ask authors/readers for more resources
IL-2 is a key cytokine during proliferation and activation of T lymphocytes and functions as an auto-and paracrine growth factor. Regardless of activating effects on T lymphocytes, the absence of IL-2 has been linked to the development of autoimmune pathology in mice and humans. Systemic lupus erythematosus (SLE) is a multifactorial autoimmune disease and characterized by dysregulation of lymphocyte function, transcription factor and cytokine expression, and antigen presentation. Reduced IL-2 expression is a hallmark of SLETlymphocytes and results in decreased numbers of regulatory T lymphocytes which play an important role in preventing autoimmunity. Reduced IL-2 expression was linked to overproduction of the transcription regulatory factor cAMP-responsive element modulator (CREM)alpha in SLE T lymphocytes and subsequent CREM alpha binding to a CRE site within the IL2 promoter (-180 CRE). In this study, we demonstrate the involvement of CREM alpha-mediated IL2 silencing inTlymphocytes from SLE patients through a gene-wide histone deacetylase 1-directed deacetylation of histone H3K18 and DNA methyltransferase 3a-directed cytosine phosphate guanosine (CpG)-DNA hypermethylation. For the first time, we provide direct evidence that CREM alpha mediates silencing of the IL2 gene in SLE T cells though histone deacetylation and CpG-DNA methylation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available